Jenny C. Chang, MD

Emily Herrmann Chair in Cancer Research & Director, Cancer Center
Professor of Medicine in Oncology, Academic Institute
Full Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Dr. Jenny C. Chang is the Director of Houston Methodist Cancer Center and Emily Herrmann Chair in Cancer Research in Houston, Texas. She obtained her medical degree at Cambridge University in England, and then completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research in the United Kingdom. She was also awarded a research doctorate from the University of London. Her recent work has focused on the intrinsic therapy resistance of cancer stem cells, which has led to several publications and international presentations. Dr. Chang’s clinical research aims to evaluate novel biologic agents in breast cancer patients.

Description of Research

Dr. Chang has worked in the field of tumor-initiating cells for more than ten years. After her discovery that tumor-initiating cells are chemo-resistant, and that targeting the EGFR/HER2 pathway can decrease this subpopulation, Dr. Chang has played a key role in demonstrating some of the limitations and mechanisms of tumor-initiating cells (Creighton et al., 2009; Li et al., 2008). Her work is now focused on the mechanisms that regulate TICs, as well as initiating and planning clinical trials that target this critical tumor initiating subpopulation. She is also interested in characterizing the cross-talk between these different pathways that may lead to mechanisms of resistance, and has identified some of the chief regulatory pathways involved in TIC self-renewal. She is a world-renown clinical investigator, credited as one of the first to describe intrinsic chemo-resistance of tumor-initiating cells.

Areas Of Expertise

Breast cancer Cancer Stem cells High throughput
Education & Training

MD, University of Cambridge
Research Doctorate, University of London

MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC
Franklin, DA, Sharick, JT, Ericsson-Gonzalez, PI, Sanchez, V, Dean, PT, Opalenik, SR, Cairo, S, Judde, JG, Lewis, MT, Chang, JC, Sanders, ME, Cook, RS, Skala, MC, Bordeaux, J, Orozco Bender, J, Vaupel, C, Geiss, G, Hinerfeld, D & Balko, JM 2020, JCI insight, vol. 5, no. 15.

Emerging treatment strategies for breast cancer brain metastasis: from translational therapeutics to real-world experience
Ren, D, Cheng, H, Wang, X, Vishnoi, M, Teh, BS, Rostomily, R, Chang, JC, Wong, ST & Zhao, H 2020, Therapeutic Advances in Medical Oncology, vol. 12.

Metastatic triple-negative breast cancer: Established and emerging treatments
Puri, A, Reddy, TP, Patel, TA & Chang, JC 2020, Breast Journal.

Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015
the Translational Breast Cancer Research Consortium (TBCRC) 2020, Breast Cancer Research and Treatment, vol. 181, no. 3, pp. 623-633.

Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer (Breast Cancer Research (2020) 22: 4 DOI: 10.1186/s13058-019-1243-8)
Goldstein, LJ, Perez, RP, Yardley, D, Han, LK, Reuben, JM, Gao, H, McCanna, S, Butler, B, Ruffini, PA, Liu, Y, Rosato, RR & Chang, JC 2020, Breast Cancer Research, vol. 22, no. 1, 52.

Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs
Reddy, TP, Choi, DS, Anselme, AC, Qian, W, Chen, W, Lantto, J, Horak, ID, Kragh, M, Chang, JC & Rosato, RR 2020, Breast cancer research : BCR, vol. 22, no. 1.

Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer
Yomtoubian, S, Lee, SB, Verma, A, Izzo, F, Markowitz, G, Choi, H, Cerchietti, L, Vahdat, L, Brown, KA, Andreopoulou, E, Elemento, O, Chang, JC, Inghirami, G, Gao, D, Ryu, S & Mittal, V 2020, Cell Reports, vol. 30, no. 3, pp. 755-770.e6.

A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer
Goldstein, LJ, Perez, RP, Yardley, D, Han, LK, Reuben, JM, Gao, H, McCanna, S, Butler, B, Ruffini, PA, Liu, Y, Rosato, RR & Chang, JC 2020, Breast Cancer Research, vol. 22, no. 1, 4.

A Deep Learning-Based Decision Support Tool for Precision Risk Assessment of Breast Cancer
He, T, Puppala, M, Ezeana, CF, Huang, Y-S, Chou, P-H, Yu, X, Chen, S, Wang, L, Yin, Z, Danforth, RL, Ensor, J, Chang, J, Patel, T & Wong, STC 2020, JCO Clinical Cancer Informatics, vol. 3, pp. 1-12.

The impact of molecular status on survival outcomes for invasive micropapillary carcinoma of the breast
Lewis, GD, Xing, Y, Haque, WM, Patel, T, Schwartz, MR, Chen, AC, Farach, AM, Hatch, SS, Butler, EB, Chang, JC & Teh, BS 2019, Breast Journal, vol. 25, no. 6, pp. 1171-1176.

Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases
Liu, ZB, Ezzedine, NE, Eterovic, AK, Ensor, Jr. JE, Huang, HJ, Albanell, J, Choi, DS, Lluch, A, Liu, Y, Rojo, F, Wong, H, Martínez-Dueñas, E, Guerrero-Zotano, Á, Shao, ZM, Darcourt, J, Mills, GB, Dave, B & Chang, JC 2019, Breast Cancer Research and Treatment, vol. 178, no. 2, pp. 251-261.

Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database
Lewis, GD, Xing, Y, Haque, WM, Patel, T, Schwartz, M, Chen, A, Farach, AM, Hatch, SS, Butler, EB, Chang, JC & Teh, BS 2019, Cancer Communications, vol. 39, no. 1, 60.

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Patel, T, Ensor, Jr. JE, Creamer, SL, Boone, T, Rodriguez, AA, Niravath, PA, Darcourt, J, Meisel, JL, Li, X, Zhao, J, Kuhn, JG, Rosato, RR, Qian, W, Belcheva, A, Schwartz, MR, Kaklamani, VG & Chang, JC 2019, Breast Cancer Research, vol. 21, no. 1, 100.

Developing a model to predict accrual to cancer clinical trials: Data from an NCI designated cancer center
Iruku, P, Goros, M, Gelfond, J, Chang, JC, Padalecki, S, Mesa, R & Kaklamani, VG 2019, Contemporary Clinical Trials Communications, vol. 15, 100421.

Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression
La Belle Flynn, A, Calhoun, BC, Sharma, A, Chang, JC, Almasan, A & Schiemann, WP 2019, Nature Communications, vol. 10, no. 1, 3668.

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer
Veeraraghavan, J, De Angelis, C, Mao, R, Wang, T, Herrera, S, Pavlick, AC, Contreras, A, Nuciforo, P, Mayer, IA, Forero, A, Nanda, R, Goetz, MP, Chang, JC, Wolff, AC, Krop, IE, Fuqua, SAW, Prat, A, Hilsenbeck, SG, Weigelt, B, Reis-Filho, JS, Gutierrez, C, Osborne, CK, Rimawi, MF & Schiff, R 2019, Annals of Oncology, vol. 30, no. 6, mdz076, pp. 927-933.

Erratum: Triple-negative breast cancers with amplication of JAK2 at the 9p24 locus demonstrate JAK2-specic dependence (Science Translational Medicine (2019) 11, 476, (eaaw6162), 10.1126/scitranslmed.aaw6162)
Balko, JM, Schwarz, LJ, Luo, N, Estrada, MV, Giltnane, JM, Dávila-González, D, Wang, K, Sánchez, V, Dean, PT, Combs, SE, Hicks, D, Pinto, JA, Landis, MD, Doimi, FD, Yelensky, R, Miller, VA, Stephens, PJ, Rimm, DL, Gómez, H, Chang, JC, Sanders, ME, Cook, RS & Arteaga, CL 2019, Science translational medicine, vol. 11, no. 476, eaaw6162.

Cancer therapeutic targeting using mutant–p53-specific siRNAs
Ubby, I, Krueger, C, Rosato, RR, Qian, W, Chang, JC & Sabapathy, K 2019, , Oncogene, vol. 38, no. 18, pp. 3415-3427.

Activating Transcription Factor 4 Modulates TGFß-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling
González-González, A, Muñoz-Muela, E, Marchal, JA, Cara, FE, Molina, MP, Cruz-Lozano, M, Jiménez, G, Verma, A, Ramírez, A, Qian, W, Chen, W, Kozielski, AJ, Elemento, O, Martín-Salvago, MD, Luque, RJ, Rosa-Garrido, C, Landeira, D, Quintana-Romero, M, Rosato, RR, García, MA, Ramirez-Tortosa, CL, Kim, H, Rodriguez-Aguayo, C, Lopez-Berestein, G, Sood, AK, Lorente, JA, Sánchez-Rovira, P, Chang, JC & Granados-Principal, S 2018, Clinical Cancer Research, vol. 24, no. 22, pp. 5697-5709.

A Behavior-Modification, Clinical-Grade Mobile Application to Improve Breast Cancer Survivors' Accountability and Health Outcomes
Stubbins, R, He, T, Yu, X, Puppala, M, Ezeana, CF, Chen, S, Valdivia y Alvarado, M, Ensor, J, Rodriguez, A, Niravath, P, Chang, J, Wong, STC & Patel, T 2018, JCO Clinical Cancer Informatics, no. 2, pp. 1-11.